Skip to content
Screener

Ligand Pharmaceuticals LGND Other income, net (Note 6)

Other income, net (Note 6) at other companies

Royalty Pharma logo
Royalty PharmaRPRX
-$1.5M+3.0%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$7.12M+10.0%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$987K+868%
Innoviva, Inc. logo
Innoviva, Inc.INVA
-$15K+98.1%
Opko Health logo
Opko HealthOPK
$1.8M+105%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
-$943K-93.2%

Other financials

Income statement

See full
Revenue$63.7M+33.7%
Operating income$8.6M+1.7%
Net income$48.5M+901%
EPS (diluted)$2.22+825%

Balance sheet

See full
Cash & equivalents$1.0B+1,388%
Total debt$1.1B+19,605%
Total equity$967.5M+16.9%
Total assets$2.2B+130%

Cash flow

See full
Operating cash flow$24.0M+52.0%
CapEx$26.0K-87.9%
Free cash flow$24.0M+53.9%

Valuation

See full
Market cap$6.02B+119%
Enterprise value$6.14B+129%
P/E30.5×
P/S20.7×+6.1×

Profitability

See full
Gross margin91.9%
Operating margin32.6%+24.0pp
Net margin67.9%+49.4pp
FCF margin45.2%+16.7pp

Returns & leverage

See full
Return on equity22%+16.9pp
Debt / equity1.2×+1.2×
Current ratio31.2×+25.7×

Where this comes from

Reported directly by Ligand Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026.

Filed
Aug 7, 2026, 4:06 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000886163-26-000044
Line itemThree months ended / June 30, 2026Three months ended / June 30, 2025Six months ended / June 30, 2026Six months ended / June 30, 2025
Gain (loss) from change in fair value of equity-method investments and other investments35,727(13,502)
Interest income7,2981,62113,9533,392
Interest expense(1,748)(1,153)(3,495)(2,020)
Other non-operating expense, net2,6821,3721,507(1,129)
Total non-operating income (expenses), net55,7132,77914,086(11,185)
Income (loss) before income taxes64,30411,22340,045(38,957)
Income tax (expense) benefit(15,796)(6,376)(4,882)1,353
Net income (loss)$48,508$4,847$35,163$(37,604)

Item 1. Condensed Consolidated Financial Statements (unaudited)

FAQ

What is Ligand Pharmaceuticals's other income, net (note 6)?
Ligand Pharmaceuticals (LGND) reported other income, net (note 6) of $2.68M in Q2 2026.
How has Ligand Pharmaceuticals's other income, net (note 6) changed year-over-year?
Ligand Pharmaceuticals's other income, net (note 6) increased by 95.5% year-over-year, from $1.37M to $2.68M.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.

Ask your AI about Ligand Pharmaceuticals's other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude